ID   DYR1B_HUMAN             Reviewed;         629 AA.
AC   Q9Y463; O75258; O75788; O75789;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   15-MAR-2017, entry version 171.
DE   RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase 1B;
DE            EC=2.7.12.1;
DE   AltName: Full=Minibrain-related kinase;
DE   AltName: Full=Mirk protein kinase;
GN   Name=DYRK1B; Synonyms=MIRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Testis;
RX   PubMed=9918863; DOI=10.1006/bbrc.1998.9967;
RA   Leder S., Weber Y., Altafaj X., Estivill X., Joost H.-G., Becker W.;
RT   "Cloning and characterization of DYRK1B, a novel member of the DYRK
RT   family of protein kinases.";
RL   Biochem. Biophys. Res. Commun. 254:474-479(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   PHOSPHORYLATION AT TYR-271 AND TYR-273, AND MUTAGENESIS OF LYS-140;
RP   TYR-271 AND TYR-273.
RC   TISSUE=Colon carcinoma;
RX   PubMed=10910078;
RA   Lee K., Deng X., Friedman E.;
RT   "Mirk protein kinase is a mitogen-activated protein kinase substrate
RT   that mediates survival of colon cancer cells.";
RL   Cancer Res. 60:3631-3637(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH DCOHM; MAP2K3 AND TCF1.
RC   TISSUE=Muscle;
RX   PubMed=11980910; DOI=10.1074/jbc.M203257200;
RA   Lim S., Jin K., Friedman E.;
RT   "Mirk protein kinase is activated by MKK3 and functions as a
RT   transcriptional activator of HNF1alpha.";
RL   J. Biol. Chem. 277:25040-25046(2002).
RN   [6]
RP   FUNCTION, DIMERIZATION, INTERACTION WITH RANBP9, AND IDENTIFICATION IN
RP   A COMPLEX WITH RAN; RANBP9 AND COPS5.
RX   PubMed=14500717; DOI=10.1074/jbc.M307556200;
RA   Zou Y., Lim S., Lee K., Deng X., Friedman E.;
RT   "Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial
RT   cell migration and is negatively regulated by the Met adaptor Ran-
RT   binding protein M.";
RL   J. Biol. Chem. 278:49573-49581(2003).
RN   [7]
RP   INTERACTION WITH DCAF7.
RX   PubMed=14593110; DOI=10.1074/jbc.M301769200;
RA   Skurat A.V., Dietrich A.D.;
RT   "Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family
RT   protein kinases.";
RL   J. Biol. Chem. 279:2490-2498(2004).
RN   [8]
RP   CATALYTIC ACTIVITY.
RX   PubMed=22998443; DOI=10.1021/jm301034u;
RA   Tahtouh T., Elkins J.M., Filippakopoulos P., Soundararajan M.,
RA   Burgy G., Durieu E., Cochet C., Schmid R.S., Lo D.C., Delhommel F.,
RA   Oberholzer A.E., Pearl L.H., Carreaux F., Bazureau J.P., Knapp S.,
RA   Meijer L.;
RT   "Selectivity, cocrystal structures, and neuroprotective properties of
RT   leucettines, a family of protein kinase inhibitors derived from the
RT   marine sponge alkaloid leucettamine B.";
RL   J. Med. Chem. 55:9312-9330(2012).
RN   [9]
RP   FUNCTION, VARIANTS AOMS3 PRO-90 AND CYS-102, AND CHARACTERIZATION OF
RP   VARIANTS AOMS3 PRO-90 AND CYS-102.
RX   PubMed=24827035; DOI=10.1056/NEJMoa1301824;
RA   Keramati A.R., Fathzadeh M., Go G.W., Singh R., Choi M., Faramarzi S.,
RA   Mane S., Kasaei M., Sarajzadeh-Fard K., Hwa J., Kidd K.K.,
RA   Babaee Bigi M.A., Malekzadeh R., Hosseinian A., Babaei M.,
RA   Lifton R.P., Mani A.;
RT   "A form of the metabolic syndrome associated with mutations in
RT   DYRK1B.";
RL   N. Engl. J. Med. 370:1909-1919(2014).
RN   [10]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-28; HIS-102; GLY-234 AND ARG-275.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual-specificity kinase which possesses both
CC       serine/threonine and tyrosine kinase activities. Enhances the
CC       transcriptional activity of TCF1/HNF1A and FOXO1. Inhibits
CC       epithelial cell migration. Mediates colon carcinoma cell survival
CC       in mitogen-poor environments. Inhibits the SHH and WNT1 pathways,
CC       thereby enhancing adipogenesis. In addition, promotes expression
CC       of the gluconeogenic enzyme glucose-6-phosphatase (G6PC).
CC       {ECO:0000269|PubMed:10910078, ECO:0000269|PubMed:11980910,
CC       ECO:0000269|PubMed:14500717, ECO:0000269|PubMed:24827035}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:22998443}.
CC   -!- ENZYME REGULATION: Inhibited by RANBP9.
CC   -!- SUBUNIT: Dimer. Interacts with DCOHM, MAP2K3/MKK3, RANBP9 and
CC       TCF1/HNF1A. Part of a complex consisting of RANBP9, RAN, DYRK1B
CC       and COPS5. Interacts with DCAF7. {ECO:0000269|PubMed:11980910,
CC       ECO:0000269|PubMed:14500717, ECO:0000269|PubMed:14593110}.
CC   -!- INTERACTION:
CC       P61962:DCAF7; NbExp=3; IntAct=EBI-634187, EBI-359808;
CC       P20823:HNF1A; NbExp=4; IntAct=EBI-634187, EBI-636034;
CC       Q9BRK4:LZTS2; NbExp=3; IntAct=EBI-634187, EBI-741037;
CC       P46734:MAP2K3; NbExp=2; IntAct=EBI-634187, EBI-602462;
CC       Q9H0N5:PCBD2; NbExp=2; IntAct=EBI-634187, EBI-634289;
CC       Q96S59:RANBP9; NbExp=4; IntAct=EBI-634187, EBI-636085;
CC       P06400:RB1; NbExp=3; IntAct=EBI-634187, EBI-491274;
CC       P28749:RBL1; NbExp=3; IntAct=EBI-634187, EBI-971402;
CC       Q12815:TROAP; NbExp=5; IntAct=EBI-634187, EBI-2349743;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9Y463-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y463-2; Sequence=VSP_004925;
CC       Name=3;
CC         IsoId=Q9Y463-3; Sequence=VSP_004926;
CC   -!- TISSUE SPECIFICITY: Highest expression in skeletal muscle, testis,
CC       heart and brain with little expression in colon or lung. Expressed
CC       in a variety of tumor cell lines. {ECO:0000269|PubMed:10910078}.
CC   -!- PTM: Autophosphorylated on tyrosine residues. Phosphorylated by
CC       MAP kinase. Tyrosine phosphorylation may be required for
CC       dimerization. {ECO:0000269|PubMed:10910078}.
CC   -!- DISEASE: Abdominal obesity-metabolic syndrome 3 (AOMS3)
CC       [MIM:615812]: A form of abdominal obesity-metabolic syndrome, a
CC       disorder characterized by abdominal obesity, high triglycerides,
CC       low levels of high density lipoprotein cholesterol, high blood
CC       pressure, and elevated fasting glucose levels. AOMS3 is
CC       characterized by early-onset coronary artery disease, central
CC       obesity, hypertension, and diabetes.
CC       {ECO:0000269|PubMed:24827035}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MNB/DYRK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC28914.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DYRK1BID43235ch19q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y17999; CAA76991.1; -; mRNA.
DR   EMBL; Y17999; CAA76990.1; -; mRNA.
DR   EMBL; Y17999; CAA76989.1; -; mRNA.
DR   EMBL; AF205861; AAF15893.1; -; mRNA.
DR   EMBL; AC005393; AAC28914.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC018751; AAH18751.1; -; mRNA.
DR   EMBL; BC025291; AAH25291.1; -; mRNA.
DR   CCDS; CCDS12543.1; -. [Q9Y463-1]
DR   CCDS; CCDS12544.1; -. [Q9Y463-3]
DR   CCDS; CCDS46075.1; -. [Q9Y463-2]
DR   PIR; JG0195; JG0195.
DR   RefSeq; NP_004705.1; NM_004714.2. [Q9Y463-1]
DR   RefSeq; NP_006474.1; NM_006483.2. [Q9Y463-2]
DR   RefSeq; NP_006475.1; NM_006484.2. [Q9Y463-3]
DR   RefSeq; XP_005259455.1; XM_005259398.4. [Q9Y463-1]
DR   UniGene; Hs.130988; -.
DR   ProteinModelPortal; Q9Y463; -.
DR   SMR; Q9Y463; -.
DR   BioGrid; 114596; 61.
DR   IntAct; Q9Y463; 54.
DR   MINT; MINT-2790122; -.
DR   STRING; 9606.ENSP00000312789; -.
DR   BindingDB; Q9Y463; -.
DR   ChEMBL; CHEMBL5543; -.
DR   GuidetoPHARMACOLOGY; 2010; -.
DR   iPTMnet; Q9Y463; -.
DR   PhosphoSitePlus; Q9Y463; -.
DR   BioMuta; DYRK1B; -.
DR   DMDM; 9296963; -.
DR   EPD; Q9Y463; -.
DR   PaxDb; Q9Y463; -.
DR   PeptideAtlas; Q9Y463; -.
DR   PRIDE; Q9Y463; -.
DR   DNASU; 9149; -.
DR   Ensembl; ENST00000323039; ENSP00000312789; ENSG00000105204. [Q9Y463-1]
DR   Ensembl; ENST00000348817; ENSP00000221803; ENSG00000105204. [Q9Y463-3]
DR   Ensembl; ENST00000430012; ENSP00000403182; ENSG00000105204. [Q9Y463-2]
DR   Ensembl; ENST00000593685; ENSP00000469863; ENSG00000105204. [Q9Y463-1]
DR   Ensembl; ENST00000597639; ENSP00000472941; ENSG00000105204. [Q9Y463-3]
DR   Ensembl; ENST00000625388; ENSP00000486839; ENSG00000281320. [Q9Y463-3]
DR   Ensembl; ENST00000625438; ENSP00000487313; ENSG00000281320. [Q9Y463-3]
DR   Ensembl; ENST00000625757; ENSP00000485915; ENSG00000281320. [Q9Y463-1]
DR   Ensembl; ENST00000627034; ENSP00000487539; ENSG00000281320. [Q9Y463-2]
DR   Ensembl; ENST00000631090; ENSP00000486377; ENSG00000281320. [Q9Y463-1]
DR   GeneID; 9149; -.
DR   KEGG; hsa:9149; -.
DR   UCSC; uc002omi.4; human. [Q9Y463-1]
DR   CTD; 9149; -.
DR   DisGeNET; 9149; -.
DR   GeneCards; DYRK1B; -.
DR   HGNC; HGNC:3092; DYRK1B.
DR   HPA; HPA028522; -.
DR   HPA; HPA028786; -.
DR   MalaCards; DYRK1B; -.
DR   MIM; 604556; gene.
DR   MIM; 615812; phenotype.
DR   neXtProt; NX_Q9Y463; -.
DR   OpenTargets; ENSG00000105204; -.
DR   PharmGKB; PA27549; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   eggNOG; ENOG410XPET; LUCA.
DR   GeneTree; ENSGT00760000119032; -.
DR   HOGENOM; HOG000220863; -.
DR   HOVERGEN; HBG051425; -.
DR   InParanoid; Q9Y463; -.
DR   KO; K08825; -.
DR   OMA; HKPAATQ; -.
DR   OrthoDB; EOG091G03J7; -.
DR   PhylomeDB; Q9Y463; -.
DR   TreeFam; TF314624; -.
DR   BioCyc; MetaCyc:HS02690-MONOMER; -.
DR   BRENDA; 2.7.12.1; 2681.
DR   SignaLink; Q9Y463; -.
DR   SIGNOR; Q9Y463; -.
DR   ChiTaRS; DYRK1B; human.
DR   GeneWiki; DYRK1B; -.
DR   GenomeRNAi; 9149; -.
DR   PRO; PR:Q9Y463; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000105204; -.
DR   CleanEx; HS_DYRK1B; -.
DR   ExpressionAtlas; Q9Y463; baseline and differential.
DR   Genevisible; Q9Y463; HS.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0060612; P:adipose tissue development; IMP:UniProtKB.
DR   GO; GO:0007520; P:myoblast fusion; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR033565; DYRK1B.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24058:SF90; PTHR24058:SF90; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Diabetes mellitus; Kinase; Nucleotide-binding; Nucleus; Obesity;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase.
FT   CHAIN         1    629       Dual specificity tyrosine-
FT                                phosphorylation-regulated kinase 1B.
FT                                /FTId=PRO_0000085934.
FT   DOMAIN      111    431       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     117    125       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     190    193       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      480    520       Interaction with RANBP9.
FT                                {ECO:0000269|PubMed:14500717}.
FT   MOTIF        69     86       Bipartite nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    558    561       Poly-Pro.
FT   ACT_SITE    239    239       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     140    140       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      63     63       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q13627}.
FT   MOD_RES      92     92       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q13627}.
FT   MOD_RES     111    111       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q13627}.
FT   MOD_RES     129    129       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q13627}.
FT   MOD_RES     262    262       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q13627}.
FT   MOD_RES     271    271       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10910078}.
FT   MOD_RES     273    273       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10910078}.
FT   MOD_RES     401    401       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q13627}.
FT   MOD_RES     624    624       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q13627}.
FT   VAR_SEQ     366    405       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:9918863}.
FT                                /FTId=VSP_004925.
FT   VAR_SEQ     378    405       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:9918863}.
FT                                /FTId=VSP_004926.
FT   VARIANT      28     28       L -> P (in dbSNP:rs34587974).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040454.
FT   VARIANT      90     90       H -> P (in AOMS3; expression of glucose-
FT                                6-phosphatase is significantly higher
FT                                than wild-type; dbSNP:rs587777380).
FT                                {ECO:0000269|PubMed:24827035}.
FT                                /FTId=VAR_071773.
FT   VARIANT     102    102       R -> C (in AOMS3; accumulation of
FT                                intracellular lipid is significantly
FT                                greater than with wild-type protein;
FT                                cells expressing the variant are able to
FT                                transform into mature adipocytes without
FT                                requiring adipogenic medium; expression
FT                                levels of CEBPA, PPARG forms 1 and 2 and
FT                                PPARGC1A are higher and those of GLI1 and
FT                                CDKN1B are lower in cells transfected
FT                                with the mutant protein compared to wild-
FT                                type; WNT1 signaling activity is lower in
FT                                mutant cells compared to wild-type;
FT                                dbSNP:rs367643250).
FT                                {ECO:0000269|PubMed:24827035}.
FT                                /FTId=VAR_071774.
FT   VARIANT     102    102       R -> H (in dbSNP:rs55687541).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040455.
FT   VARIANT     234    234       S -> G (in dbSNP:rs35858874).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040456.
FT   VARIANT     275    275       Q -> R (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040457.
FT   MUTAGEN     140    140       K->R: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:10910078}.
FT   MUTAGEN     271    271       Y->F: Abolishes kinase activity; when
FT                                associated with F-273.
FT                                {ECO:0000269|PubMed:10910078}.
FT   MUTAGEN     273    273       Y->F: Abolishes kinase activity; when
FT                                associated with F-271.
FT                                {ECO:0000269|PubMed:10910078}.
SQ   SEQUENCE   629 AA;  69198 MW;  D7C354AC55943A8B CRC64;
     MAVPPGHGPF SGFPGPQEHT QVLPDVRLLP RRLPLAFRDA TSAPLRKLSV DLIKTYKHIN
     EVYYAKKKRR AQQAPPQDSS NKKEKKVLNH GYDDDNHDYI VRSGERWLER YEIDSLIGKG
     SFGQVVKAYD HQTQELVAIK IIKNKKAFLN QAQIELRLLE LMNQHDTEMK YYIVHLKRHF
     MFRNHLCLVF ELLSYNLYDL LRNTHFRGVS LNLTRKLAQQ LCTALLFLAT PELSIIHCDL
     KPENILLCNP KRSAIKIVDF GSSCQLGQRI YQYIQSRFYR SPEVLLGTPY DLAIDMWSLG
     CILVEMHTGE PLFSGSNEVD QMNRIVEVLG IPPAAMLDQA PKARKYFERL PGGGWTLRRT
     KELRKDYQGP GTRRLQEVLG VQTGGPGGRR AGEPGHSPAD YLRFQDLVLR MLEYEPAARI
     SPLGALQHGF FRRTADEATN TGPAGSSAST SPAPLDTCPS SSTASSISSS GGSSGSSSDN
     RTYRYSNRYC GGPGPPITDC EMNSPQVPPS QPLRPWAGGD VPHKTHQAPA SASSLPGTGA
     QLPPQPRYLG RPPSPTSPPP PELMDVSLVG GPADCSPPHP APAPQHPAAS ALRTRMTGGR
     PPLPPPDDPA TLGPHLGLRG VPQSTAASS
//
